Part A: Geometric mean titer of serum neutralization titers against pseudovirus bearing Omicron subvariant XX spike protein;Part A: Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Part A: Percentage of participants with adverse events of special interest (AESIs);Part A: Percentage of participants with medically attended adverse events (MAAEs);Part A: Percentage of participants with serious adverse events (SAEs);Part A: Percentage of participants with solicited administration site adverse events (AEs);Part A: Percentage of participants with solicited administration systemic AEs;Part A: Percentage of participants with unsolicited AEs;Part B: Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Part B: Percentage of participants with adverse events of special interest (AESIs) Part B: Percentage of participants with adverse events of special interest (AESIs);Part B: Percentage of participants with medically attended adverse events (MAAEs);Part B: Percentage of participants with serious adverse events (SAEs);Part B: Percentage of participants with solicited administration site adverse events (AEs);Part B: Percentage of participants with solicited administration systemic AEs;Part B: Percentage of participants with unsolicited AEs

Part A: Geometric mean titer of serum neutralization titers against pseudovirus bearing Omicron subvariant XX spike protein;Part A: Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Part A: Percentage of participants with adverse events of special interest (AESIs);Part A: Percentage of participants with medically attended adverse events (MAAEs);Part A: Percentage of participants with serious adverse events (SAEs);Part A: Percentage of participants with solicited administration site adverse events (AEs);Part A: Percentage of participants with solicited administration systemic AEs;Part A: Percentage of participants with unsolicited AEs;Part B: Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Part B: Percentage of participants with adverse events of special interest (AESIs) Part B: Percentage of participants with adverse events of special interest (AESIs);Part B: Percentage of participants with medically attended adverse events (MAAEs);Part B: Percentage of participants with serious adverse events (SAEs);Part B: Percentage of participants with solicited administration site adverse events (AEs);Part B: Percentage of participants with solicited administration systemic AEs;Part B: Percentage of participants with unsolicited AEs

Geometric mean titer of serum neutralization titers against pseudovirus bearing Omicron subvariant XX spike protein;Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Percentage of participants with adverse events of special interest (AESIs);Percentage of participants with medically attended adverse events (MAAEs);Percentage of participants with serious adverse events (SAEs);Percentage of participants with solicited administration site adverse events (AEs);Percentage of participants with solicited administration systemic AEs;Percentage of participants with unsolicited AEs

Geometric mean titer of serum neutralization titers against pseudovirus bearing Omicron subvariant XX spike protein;Geometric mean titer of serum neutralization titers against pseudovirus bearing SARS-CoV-2 strain XY spike protein;Percentage of participants with adverse events of special interest (AESIs);Percentage of participants with medically attended adverse events (MAAEs);Percentage of participants with serious adverse events (SAEs);Percentage of participants with solicited administration site adverse events (AEs);Percentage of participants with solicited administration systemic AEs;Percentage of participants with unsolicited AEs